Skip to content
Sleep & circadian healthRandomised trial3 min read

Ear vagus nerve stimulation beat sham for chronic insomnia scores in a small trial

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Insomnia Disorder: A Randomized Clinical Trial. · JAMA network open · 2024 · Original paper ↗

Key takeaway

In a randomized trial of 72 people with chronic insomnia in Beijing, ear-based vagus nerve stimulation (taVNS) lowered the PSQI sleep score 4.2 points more than sham (95% CI -5.9 to -2.6; P < .001). The trial was small, single-center, and the sham group also improved, so wider benefit is unproven.

Study design

Randomised trial

Reading basis

Published abstract

Reading focus

Comparator & uncertainty

The research question

Chronic insomnia is hard to treat with drugs and talk therapy alone, and randomized evidence for transcutaneous auricular vagus nerve stimulation (taVNS), a device that sends mild current to the ear, was lacking. The authors tested its efficacy and safety against sham stimulation.

Who and how

Randomized clinical trial at a single center in Beijing, China, from October 2021 to December 2022. Adults with chronic insomnia disorder and a Pittsburgh Sleep Quality Index (PSQI) of at least 8 were allocated 1:1 to active or sham taVNS, 30 minutes per session, twice a day, 5 consecutive days a week, for 8 weeks of treatment with 12 weeks of follow-up. The primary outcome was the mean change in PSQI from baseline through week 8; secondary outcomes covered mental health, sleepiness and fatigue, and safety. Registered as ChiCTR2100051319.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    72 participants were randomized: 36 to active taVNS (mean age 45.2, 27 [75.0%] female) and 36 to sham (mean age 44.6, 31 [86.1%] female); 68 completed the 8-week intervention.
  2. 2
    PSQI fell by 8.2 points (95% CI -9.3 to -7.0) with taVNS and by 3.9 points (95% CI -5.1 to -2.7) with sham, so both groups improved.
  3. 3
    The between-group difference was 4.2 points (95% CI -5.9 to -2.6; P < .001; Cohen d 1.2), larger than the 2.5-point minimal clinically important difference.
  4. 4
    Secondary outcomes, including mental health and fatigue, showed similar favorable results, and the effect was sustained through the 20-week study period.

Limits & uncertainty

  1. 1
    Only 72 people were randomized at one center in Beijing, so the findings may not apply to other populations; the authors call for larger multicenter trials.
  2. 2
    Sleep quality was scored by a questionnaire (PSQI) rather than objectively recorded sleep, and the abstract does not say whether participants could tell which device they had.
  3. 3
    The sham group improved by 3.9 points, so a notable part of the change may come from expectation or the treatment routine rather than the stimulation itself.
  4. 4
    This reading is based on the abstract only.

What to take from it

This is an encouraging early signal that stimulating the ear could ease insomnia, but a single small trial is not enough to recommend a device. Treatment choices for chronic insomnia, including whether to use a taVNS device, should be made with a clinician.

Reading your own data

The trial judged sleep by the PSQI questionnaire, so your own check could be a weekly PSQI-style self-rating or sleep diary. Wearables can show total sleep time and bedtime consistency, but they estimate sleep stages poorly. Compare your own weeks on the same device and look at trends rather than single nights.

How to read this evidence

Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Importance

Evidence from randomized clinical trials of transcutaneous auricular vagus nerve stimulation (taVNS) for chronic insomnia disorder is lacking.

Objective

To evaluate the efficacy and safety of taVNS for chronic insomnia compared with the sham taVNS.

Design, setting, and participants

This randomized clinical trial was conducted from October 2021 to December 2022 at a single center in Beijing, China. Patients with chronic insomnia disorder with a Pittsburgh Sleep Quality Index (PSQI) of at least 8 were enrolled. Statistical analysis was performed from June to September 2023.

Interventions

Patients were allocated to the active taVNS group or sham taVNS group with a 1:1 ratio. Both groups received the stimulation for 30 minutes each time, twice a day, 5 consecutive days a week, with an 8-week treatment and a 12-week follow-up.

Main outcomes and measures

The primary end point was the mean change from baseline through week 8 in PSQI scores. Minimal clinically important difference was 2.5 points. Secondary outcomes included mental health, sleepiness, and fatigue. Safety was also evaluated.

Results

A total of 72 participants were randomized to either active taVNS group (36 participants; mean [SD] age, 45.2 [14.5] years; 27 [75.0%] female) or the sham taVNS group (36 participants; mean [SD] age, 44.6 [13.9] years; 31 [86.1%] female); 68 participants completed the 8-week intervention. The least-square mean changes from baseline to week 8 in PSQI were -8.2 (95% CI, -9.3 to -7.0) points in the taVNS group and -3.9 (95% CI, -5.1 to -2.7) points in the sham group. Both groups experienced statistically significant improvements from before to after the intervention. However, active taVNS showed a clinically meaningful 4.2-point greater reduction (95% CI, -5.9 to -2.6 points; P < .001; Cohen d effect size, 1.2) in PSQI compared with the sham group (minimal clinically important difference = 2.5 points). Secondary outcomes, including mental health and fatigue, showed similar favorable results. The efficacy of taVNS was sustained throughout the 20-week study period.

Conclusions and relevance

In this randomized clinical trial, taVNS significantly reduced insomnia severity. Clinically meaningful enhancements in PSQI scores were observed compared with sham stimulation, with the benefits of taVNS sustained over a 20-week period. Future multicenter clinical trials with large sample sizes are needed to validate its effectiveness across diverse populations.

Trial registration

Chinese Clinical Trial Registry: ChiCTR2100051319.

Sources & attribution

Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Insomnia Disorder: A Randomized Clinical Trial.

Zhang S, Zhao Y, Qin Z, Han Y, He J, Zhao B, Wang L, Duan Y, Huo J, Wang T, Wang Y, Rong P.

JAMA network open · 2024-12-02

DOI: 10.1001/jamanetworkopen.2024.51217 ↗PubMed · 39680406 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Trial meta-analysis

Exercise improved sleep-quality scores in adults 45 and older with sleep disorders

Pooling 23 randomized trials with 1,478 adults aged 45 to 77 who had sleep disorders, exercise improved Pittsburgh Sleep Quality Index scores (SMD 0.62, 95% CI 0.40–0.83), and aerobic exercise showed the largest effect in the network analysis (SMD 1.34, 95% CrI 0.86–1.82). Certainty was low to moderate, the outcomes were questionnaires, and the best weekly dose of about 539 MET-min/week is a model estimate, not a prescription.

Journal of Exercise Science & Fitness

In-depth explainersRead study →
·Cohort study

Sleep regularity tracked mortality more closely than sleep duration in 60,977 UK adults

Among 60,977 UK Biobank adults who wore a wrist accelerometer for a week, the most regular fifth of sleepers had a fully adjusted all-cause mortality HR of 0.70 (95% CI 0.59–0.83) against the least regular fifth, over about 6.3 years and 1859 deaths. Regularity fitted the data better than sleep duration, but the study is observational and rests on one week of sleep data.

Sleep

In-depth explainersRead study →
·Randomised trial

Sleep extension cut daily energy intake by about 270 kcal in adults with overweight

In 80 adults with overweight who usually slept under 6.5 hours, two weeks of sleep-extension counselling added about 1.2 hours of sleep and lowered measured energy intake by 270.4 kcal/d versus control (95% CI −393.4 to −147.4). The trial was short, single-centre and in a narrow group, so it does not show lasting weight loss or any benefit for people who already sleep enough.

JAMA Internal Medicine

In-depth explainersRead study →
·Cohort study

Six hours or less of sleep at 50 and 60 linked to higher dementia risk

In 7959 British civil servants followed for about 25 years, sleeping six hours or less at age 50 (HR 1.22, 95% CI 1.01–1.48) or age 60 (HR 1.37, 1.10–1.72) was linked to a higher dementia rate than sleeping seven hours, and persistent short sleep gave an HR of 1.30 (1.00–1.69). Sleep was mostly self-reported and the study is observational, so early brain disease or other factors may explain part of the link.

Nature Communications

In-depth explainersRead study →
Sleep & circadian health →